Skip to main content
RT @DrCassySims: Think about checking Ig levels prior to Rituximab administration. Low IgM was most common after RTX in

Catherine Sims, MD DrCassySims

3 years 10 months ago
Think about checking Ig levels prior to Rituximab administration. Low IgM was most common after RTX in RA. The following are risk factors for hypogammaglobulinemia: 🧪 Older age 🧪 Use of steroids 🧪 Repeated doses of RTX 🧪 Low Ig at baseline https://t.co/oOjqnmFdYt
RheumNow #ACR22 reporter, Dr. Bella Mehta, will be covering SLE, gout and auto inflammatory topics this year.

“I am l

Dr. John Cush RheumNow

3 years 10 months ago
RheumNow #ACR22 reporter, Dr. Bella Mehta, will be covering SLE, gout and auto inflammatory topics this year. “I am looking forward to meeting collegues at ACR after 2 years!” -Dr. Mehta Follow @bella_mehta for real-time coverage during #ACR22. https://t.co/QQM2NrObPR
The American College of Rheumatology (ACR) has released Continuing Medical Education (CME) for dermatologists and nephrologists to help them learn more about clinical trials for lupus patients in their respective treatment areas and the importance of getting more of their African American/Black patients enrolled.
Follow our newest #ACR22 reporter, Dr. Julian Segan ( @JulianSegan)!

“I am looking forward to is meeting all my rheu

Dr. John Cush RheumNow

3 years 10 months ago
Follow our newest #ACR22 reporter, Dr. Julian Segan ( @JulianSegan)! “I am looking forward to is meeting all my rheumatology Twitter heroes!” Follow @RheumNow and our reporters for real-time #ACR22 coverage. https://t.co/7axxfOV6W8
Remission often invites consideration of drug withdrawal in patients with axial spondyloarthritis (axSpA). Now an open label study of ixekizumab (IXE) treated axSpA patients in remission has shown that the vast majority of IXE withdrawal patients who later flared were able to recapture disease control. 
China study of 109 w/ MPO+ vasculitis (MPO-AAV), 23 w/ anti-GBM & 20 Double positive (MPO+ GBM+) (DPP) pts showed DP

Dr. John Cush RheumNow

3 years 10 months ago
China study of 109 w/ MPO+ vasculitis (MPO-AAV), 23 w/ anti-GBM & 20 Double positive (MPO+ GBM+) (DPP) pts showed DPP pts were older(p=0.007), higher creatinine & lower GFR, & had multi-organ damage (cardiac) outside the kidney https://t.co/3aGPnfVDrs https://t.co/E557RLogCE
Drug-induced Hepatotoxicity - many Rheum drugs on the list: Tylenol, azathioprine, allopurinol, cyclosporine, dapsone, g

Dr. John Cush RheumNow

3 years 10 months ago
Drug-induced Hepatotoxicity - many Rheum drugs on the list: Tylenol, azathioprine, allopurinol, cyclosporine, dapsone, gold, MTX, 6-MP, NSAIDs, ASA, SSZ, Minocin... https://t.co/wuoVrDgesq https://t.co/SAWPdsQ6I3
What is RheumNow ACR reporter, Dr. Rachel Tate, most looking forward to at #ACR22?

“Onsite, in person learning!”

F

Dr. John Cush RheumNow

3 years 10 months ago
What is RheumNow ACR reporter, Dr. Rachel Tate, most looking forward to at #ACR22? “Onsite, in person learning!” Follow @uptoTate for real-time #ACR22 coverage! https://t.co/nMw015dpdl
Evidence on gender equity in academic rheumatology in Europe is currently limited. This knowledge gap has a direct effect on the ability of professional bodies to improve gender equity. To address this, EULAR designed a study using web-based surveys to collect information; here are the results.
Alcohol consumption is a leading preventable cause of death in the U.S.  A JAMA cross-sectional study suggests that between 2015 and 2019, an estimated 1 in 8 total deaths among U.S. adults ages 20 to 64 were attributable to excessive alcohol use, including 1 in 5 deaths among adults ages 20 to 49. 
Opportunistic infections in #PsA pts on b/tsDMARDS is low. Metanalysis 47 studies, 17,197 pts - OI risk by MOA:1) JAK i

Dr. John Cush RheumNow

3 years 10 months ago
Opportunistic infections in #PsA pts on b/tsDMARDS is low. Metanalysis 47 studies, 17,197 pts - OI risk by MOA:1) JAK inhib 2.72%, 2) anti-IL-17 1.18%, 3) anti-IL-23 0.24% , 4) TNFi 0.01%. H. zoster w/ JAKi= 2.53% & Candida risk w/ IL-17=0.97% https://t.co/a5fJcWTxnL https://t.co/GQKoV7Hg6m
GSK announced they will halt development of Otilimab (anti-GM-CSF mAb) to treat #RA; decisioin based on negative results

Dr. John Cush RheumNow

3 years 10 months ago
GSK announced they will halt development of Otilimab (anti-GM-CSF mAb) to treat #RA; decisioin based on negative results from phase 3 ContRAst-3 study, that failed to meet ACR20 primary endpoint in RA pts who failed bDMARDs or JAKi https://t.co/cDqcYKOjSa https://t.co/7rB4TYsWnZ
Infection: a Leading Cause of Death in Lupus

Analysis of a national database of hospital discharges from Spain shows t

Dr. John Cush RheumNow

3 years 10 months ago
Infection: a Leading Cause of Death in Lupus Analysis of a national database of hospital discharges from Spain shows that infections accounted for 25% of lupus deaths, making infection the most common cause of death in SLE. https://t.co/uTQd3afwxR https://t.co/okBHWel62d
What's Dr. Dao looking most forward to at #ACR2022?
"To covering the meeting and learning of new developments in rheuma

Dr. John Cush RheumNow

3 years 10 months ago
What's Dr. Dao looking most forward to at #ACR2022? "To covering the meeting and learning of new developments in rheumatology. I am also excited to mentor my medical student on her first ACR meeting where she will be presenting a poster on social media in medical education.' https://t.co/27PcSmJUZe
Join Dr. Jack Cush and Dr. Arthur Kavanaugh as they discuss, dissect and deliberate about data presented at the #ACR2022

Dr. John Cush RheumNow

3 years 10 months ago
Join Dr. Jack Cush and Dr. Arthur Kavanaugh as they discuss, dissect and deliberate about data presented at the #ACR2022 meeting in Philadelphia. https://t.co/yCMStA8yQm https://t.co/myS0sT9BMq
×